The Second Laminin G-type Domain of Protein S Is Indispensable for Expression of Full Cofactor Activity in Activated Protein C-catalysed Inactivation of Factor Va and Factor VIIIa

Petra Evenäs; Pablo García de Frutos; Gerry A. F. Nicolaes; Björn Dahlbäck

doi:10.1055/s-0037-1614007

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2000; 84(02): 271-277
DOI: 10.1055/s-0037-1614007

Review Article

Schattauer GmbH

The Second Laminin G-type Domain of Protein S Is Indispensable for Expression of Full Cofactor Activity in Activated Protein C-catalysed Inactivation of Factor Va and Factor VIIIa

Petra Evenäs

²European Molecular Biology Laboratory, Via Ramarini 32, I-00016 Monterotondo (Roma), Italy

,

Pablo García de Frutos

¹From the Department of Clinical Chemistry, Wallenberg Laboratory, Lund University, University Hospital, Malmö, Sweden

²European Molecular Biology Laboratory, Via Ramarini 32, I-00016 Monterotondo (Roma), Italy

,

Gerry A. F. Nicolaes

²European Molecular Biology Laboratory, Via Ramarini 32, I-00016 Monterotondo (Roma), Italy

,

Björn Dahlbäck

²European Molecular Biology Laboratory, Via Ramarini 32, I-00016 Monterotondo (Roma), Italy

› Author Affiliations

Abstract

Summary

Vitamin K-dependent protein S is a cofactor to the anticoagulant serine protease activated protein C (APC) in the proteolytic inactivation of the procoagulant, activated factor V (FVa) and factor VIII (FVIIIa). In the FVa degradation, protein S selectively accelerates the cleavage at Arg306, having no effect on the Arg506 cleavage. In the FVIIIa inactivation, the APC-cofactor activity of protein S is synergistically potentiated by FV, which thus has the capacity to function both as a pro- and an anticoagulant protein. The SHBG-like region of protein S, containing two laminin G-type domains, is required for the combined action of protein S and FV. To elucidate whether both G domains in protein S are needed for expression of APC-cofactor activities, chimeras of human protein S were created in which the individual G domains were replaced by the corresponding domain of the homologous Gas6, which in itself has no anticoagulant activity. In a plasmabased assay, chimera I (G1 from Gas6) was as efficient as wild-type recombinant protein S, whereas chimera II (G2 from Gas6) was less effective. The synergistic cofactor activity with FV in the inactivation of FVIIIa was lost by the replacement of the G2 domain in protein S (chimera II). However, chimera I did not exert full APC-cofactor activity in the FVIIIa degradation, indicating involvement of both G domains or the entire SHBG-like region in this reaction. Chimera I was fully active in the degradation of FVa in contrast to chimera II, which exhibited reduced cofactor activity compared to protein S. In conclusion, by using protein S-Gas6 chimeric proteins, we have identified the G2 domain of protein S to be indispensable for an efficient inactivation of both FVIIIa and FVa, whereas the G1 domain was found not to be of direct importance in the FVa-inactivation experiments.

Key words

APC-cofactor activity - factor V - G domains - protein S - SHBG-like region

Full Text

References

References
1 Tans G, Nicolaes GAF, Rosing J. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation. Semin Hematol 1997; 34: 244-55.
2 Dahlbäck B, Stenflo J. The Protein C anticoagulant system. In: Stammatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H. eds. WB Saunders company; Molecular Basis of Blood Disease. Third ed. Philadelphia: 2000. in press.
3 Rosing J, Hoekema L, Nicolaes GAF, Thomassen MCLGD, Hemker HC, Váradi K, Schwarz HP, Tans G. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 27852-8.
4 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
5 Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/ protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-17.
6 Walker FJ, Chavin SI, Fay PJ. Inactivation of FVIIIa by activated protein C and protein S. Arch Biochem Biophys 1987; 252: 322-8.
7 Váradi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of FVIII: Influence of the Factor VR506Q mutation. Thromb Haemost 1996; 76: 208-14.
8 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-80.
9 Nicolaes GAF, Tans G, Thomassen MCLGD, Hemker HC, Pabinger I, Váradi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-66.
10 Lundwall Å, Dackowski W, Cohen E, Shaffer M, Mahr A, Dahlbäck B, Stenflo J, Wydro R. Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation. Proc Natl Acad Sci U.S.A 1986; 83: 6716-20.
11 Gershagen S, Fernlund P, Lundwall Å. A cDNA coding for human sex hormone binding globulin. Homology to vitamin K-dependent protein S. FEBS Letters 1987; 220: 129-35.
12 Joseph DR, Baker ME. Sex hormone-binding globulin, androgen-binding protein, and vitamin K-dependent protein S are homologous to laminin A, merosin, and Drosophila crumbs protein. FASEB 1992; 06: 2477-81.
13 Villoutreix BO, García de Frutos P, Lövenklev M, Linse S, Fernlund P, Dahlbäck B. SHBG region of the anticoagulant cofactor protein S: secondary structure prediction, circular dichroism, spectroscopy, and analysis of naturally occurring mutations. Proteins 1997; 29: 478-91.
14 Talts JF, Mann K, Yamada Y, Timpl R. Structural analysis and proteolytic processing of recombinant G domain of mouse laminin α2 chain. FEBS Letters 1998; 426: 71-6.
15 Aiach M, Borgel D, Gaussem P, Emmerich J, Alhenc-Gelas M, Gandrille S. Protein C and protein S deficiencies. Semin Hematol 1997; 34: 205-17.
16 Walker FJ. Regulation of protein C by protein S: The role of phospholipid in FVa inactivation. J Biol Chem 1981; 256: 11128-31.
17 Yegneswaran S, Wood GM, Esmon CT, Johnson AE. Protein S alters the active site location of activated protein C above the membrane. J Biol Chem 1997; 272: 25013-21.
18 Dahlbäck B, Hildebrand B, Malm J. Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. J Biol Chem 1990; 265: 8127-35.
19 He X, Shen L, Dahlbäck B. Expression and functional characterization of chimeras between human and bovine vitamin-K-dependent protein Sdefining modules important for the species specificity of the activated protein C cofactor activity. Eur J Biochem 1995; 227: 433-40.
20 He X, Shen L, Villoutreix BO, Dahlbäck B. Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function. J Biol Chem 1998; 273: 27449-58.
21 Nyberg P, Dahlbäck B, García de Frutos P. The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function. FEBS Letters 1998; 433: 28-32.
22 Koppelman SJ, van’t Veer C, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activation by protein S: Evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 2653-60.
23 Mitchell CA, Kelemen SM, Salem HH. The anticoagulant properties of a modified form of protein S. Thromb. Haemost 1988; 60: 298-304.
24 Schneider C, King RM, Philipson L. Genes specifically expressed at growth arrest of mammalian cells. Cell 1988; 54: 787-93.
25 Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin Kdependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993; 13: 4976-85.
26 Goruppi S, Ruaro E, Schneider C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 1996; 12: 471-80.
27 McCloskey P, Friedell Y-W, Attar E, Villa J, Jin Y, Varnum B, Liu ET. Gas6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl. J Biol Chem 1997; 272: 23285-91.
28 Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail G, Clogson C, Toso RJ, Yanagihara D, Bennett L, Sylber M, Merewether LA, Tseng A, Escobar E, Liu ET, Yamane HK. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995; 373: 623-6.
29 Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H, Hammonds RG. Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3. Cell 1995; 82: 355-8.
30 Chen J, Carey K, Godowski PJ. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 1997; 14: 2033-9.
31 Rosing J, Bakker HM, Thomassen MCLGD, Hemker HC, Tans G. Characterization of two forms of human FVa with different cofactor activities. J Biol Chem 1993; 268: 21130-6.
32 Persson E, Hogg PJ, Stenflo J. Effects of Ca2+ binding on the protease module of factor Xa and its interaction with factor Va. Evidence for two Gla-independent Ca(2+)-binding sites in factor Xa. J Biol Chem 1993; 268: 22531-9.
33 Evenäs P, García de Frutos P, Linse S, Dahlbäck B. Both G-type domains of protein S are required for the high-affinity interaction with C4b-binding protein. Eur J Biochem 1999; 266: 935-42.
34 Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93: 2552-8.
35 Kaufman RJ. Vectors used for expression in mammalian cells. Methods Enzymol 1990; 185: 487-511.
36 Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986; 261: 12022-7.
37 Tans G, Rosing J, Thomassen MCLGD, Heeb MJ, Zwaal RFA, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-8.
38 Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-83.
39 Malm J, Cohen E, Dackowski W, Dahlbäck B, Wydro R. Expression of completely γ-carboxylated and β-hydroxylated recombinant human vitamin K-dependent protein S with full biological activity. Eur J Biochem 1990; 187: 737-43.
40 Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 1980; 255: 5521-4.
41 Egan JO, Kalafatis M, Mann KG. The effect of Arg306→Ala and Arg506→Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Sci 1997; 06: 2016-27.
42 Heeb MJ, Rehemtulla A, Moussali M, Kojima Y, Kaufman RJ. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation. Eur J Biochem 1999; 260: 64-75.
43 Deutzmann R, Huber H, Schmelz KA, Oberbäumer I, Hatl L. Structural study of long arm fragments of laminin. Evidence for repetitive C-terminal sequences in the A-chain, not present in the B-chains. Eur J Biochem 1988; 177: 35-45.
44 Noonan DM, Fulle A, Valente P, Cai S, Horigan E, Sasaki M, Yamada Y, Hassel JR. The complement sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, LDL-receptor and N-CAM. J Biol Chem 1991; 266: 22939-47.
45 Rothberg JM, Artavanis-Tsakonas S. Modularity of the slit protein. Characterization of a conserved carboxy-terminal sequence in secreted proteins and a motif implicated in extracellular protein interactions. J Mol Biol 1992; 227: 367-70.
46 Ushkaryov YA, Petrenko AG, Geppert M, Südhof TC. Neurexins: Synaptic cell surface proteins related to the α-lactrotoxin receptor and laminin. Science 1992; 257: 50-6.
47 Beckmann G, Hanke J, Bork P, Reich JG. Merging extracellular domains: Fold prediction for laminin G-like amino-terminal thrombospondin-like modules based on homology to pentraxins. J Mol Biol 1998; 275: 725-30.
48 He X, Shen L, Malmborg A-C, Smith KJ, Dahlbäck B, Linse S. Binding site for C4b-binding protein in vitamin K-dependent protein S fully contained in carboxy-terminal laminin G-type-repeats. A study using recombinant factor IX-protein S chimeras and surface plasmon resonance. Biochemistry 1997; 36: 3745-54.
49 Evenäs P, Dahlbäck B, García de Frutos P. The first laminin G-type domain in the SHBG-like region of protein S contains residues essential for activation of the receptor tyrosine kinase Sky. Biol Chem 2000; 381: 199-209.
50 Rudenko G, Nguyen T, Chelliah Y, Südhof TC, Deisenhofer J. The structure of the ligand-binding domain of Neurexin Ib: Regulation of LNS domain function by alternative splicing. Cell 1999; 99: 93-101.